The synthetic drug plasmochin, sometimes spelled plasmoquine, was developed in 1915. It is said to be (6 methoxy 8 αa methyl γ diethylamino butyl) aminoquinoline. Thus, although it contains quinoline, it is not synthetic quinine.
At first this synthetic remedy was sold as plasmochin simplex. Later, quinine was added to it, and the combined product was called plasmochin compound. Finally, a larger percentage of quinine was added, and the mixture was sold as plasmochin with quinine salts. The latter has also been called quinoplasmoquine. At one time it was called beprochin.
Plasmochin is sold in the following forms:
1. Plasmochin simplex or plain: A salt of plasmochin, which is usually sold in bottles of twenty-five tablets, each tablet containing the equivalent of 0.02 Gm., or ⅓ grain, of plasmochin hydrochloride.
2. Plasmochin compound: Usually marketed in bottles of fifty tablets. Each tablet contains the equivalent of 0.01 Gm., or ⅙
RUSSELL PF. PLASMOCHIN, PLASMOCHIN WITH QUININE SALTS AND ATABRINE IN MALARIA THERAPY. Arch Intern Med (Chic). 1934;53(2):309–320. doi:10.1001/archinte.1934.00160080146006
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: